市場調查報告書
商品編碼
1029212

特發性肺纖維化治療的全球市場:行業趨勢、市場份額、市場規模、增長、機會、預測(2021-2026)

Idiopathic Pulmonary Fibrosis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球特發性肺纖維化治療市場的規模從 2015 年到 2020 年呈現強勁增長。展望未來,市場預計在 2026 年將達到 49.1 億美元。

隨著世界人口老齡化,纖維化日益流行是推動市場增長的重要因素之一。此外,生活方式的改變和煙草等尼古丁產品消費的增加也在推動市場增長。

吸煙和香煙被認為是發生特發性肺纖維化的最常見原因之一。與此同時,人們對特發性肺纖維化有效管理策略的健康意識也在提高,這也支持了市場的增長。

本報告探討了全球特發性肺纖維化治療市場,並提供了全面的信息,包括市場概況、市場分析、價格分析、競爭格局和公司概況。

目錄

第一章前言

第二章範圍和調查方法

第 3 章執行摘要

第 4 章介紹

第 5 章全球特發性肺纖維化治療市場

  • 市場概覽
  • 市場表現
  • COVID-19 的影響

第 6 章市場細分:按藥物類別

  • MAPK 抑製劑
  • 酪氨酸抑製劑
  • 自分泌運動因子抑製劑

第 7 章市場細分:按最終用戶

  • 醫院
  • 長期護理機構
  • 其他

第 8 章市場細分:按地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場細分:按國家/地區

第 9 章 SWOT 分析

第10章價值鏈分析

第11章波特五力分析

第12章價格分析

第十三章競爭形勢

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • AdAlta Pty Ltd.
    • Angion Biomedica Corp.
    • Boehringer Ingelheim International GmbH(C. H. Boehringer Sohn AG & Co. KG)
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • F. Hoffmann-La Roche AG(Roche Holding AG)
    • Fibrogen Inc.
    • Galapagos NV
    • Liminal BioSciences Inc.
    • Medicinova Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Vectura Group Plc
目錄
Product Code: SR1020F162_Report

The global idiopathic pulmonary fibrosis treatment market exhibited strong growth during 2015-2020. Idiopathic pulmonary fibrosis (IPF) refers to a progressive and irreversible fibrosing interstitial pneumonia that directly impacts the functioning of the lungs. It is characterized by the formation of scar tissue within the lungs that starts at the edges and progresses toward the center, thus causing difficulties in breathing and insufficient delivery of oxygen to the body parts. It is diagnosed through chest imaging studies, lung biopsies, pulmonary function tests and antibody tests. Two of the most commonly used antifibrotic therapy includes nintedanib and pirfenidone-based drugs, which improves lung functioning and minimizes the risks of acute respiratory deterioration. They are often coupled with oxygen therapy and palliative care to provide comfort and improve the recovery of the patient.

The increasing prevalence of fibrotic diseases, along with the rising geriatric population across the globe, is one of the key factors driving the growth of the market. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products, such as cigarettes, is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes is considered as one of the most common causes for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favoring the growth of the market. Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market further. Looking forward, IMARC Group expects the global idiopathic pulmonary fibrosis treatment market to reach a value of US$ 4.91 Billion by 2026.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global idiopathic pulmonary fibrosis treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug class and end user.

Breakup by Drug Class:

  • MAPK Inhibitors
  • Tyrosine Inhibitors
  • Autotaxin Inhibitors

Breakup by End User:

  • Hospitals
  • Long-term Care Facilities
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.

Key Questions Answered in This Report:

  • How has the global idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global idiopathic pulmonary fibrosis treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global idiopathic pulmonary fibrosis treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Idiopathic Pulmonary Fibrosis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 MAPK Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Tyrosine Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Autotaxin Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Long-term Care Facilities
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AdAlta Pty Ltd.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
    • 13.3.2 Angion Biomedica Corp.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Cipla Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 Fibrogen Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Galapagos NV
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Liminal BioSciences Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
    • 13.3.10 Medicinova Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Merck & Co. Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Novartis AG
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Vectura Group Plc
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2020
  • Figure 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2020
  • Figure 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 7: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 8: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 9: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: North America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: North America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Canada: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Canada: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: China: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: China: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: Australia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: Australia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: Germany: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: France: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: France: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: Italy: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: Spain: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: Russia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: Russia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
  • Figure 68: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
  • Figure 69: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2021-2026
  • Table 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market Structure
  • Table 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players